lobeglitazone and Liver-Diseases

lobeglitazone has been researched along with Liver-Diseases* in 1 studies

Other Studies

1 other study(ies) available for lobeglitazone and Liver-Diseases

ArticleYear
Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone.
    Clinical pharmacology in drug development, 2022, Volume: 11, Issue:5

    In this open-label, single-dose, parallel-group study, we compared the pharmacokinetic profile and safety of lobeglitazone, a thiazolidinedione acting as an agonist for peroxisome proliferator-activated receptors, in patients with hepatic impairment (HI) and healthy matched controls for age, sex, and body weight. After a single oral dose of lobeglitazone (0.5 mg), the lobeglitazone (parent drug) and M7 (major metabolite) plasma concentrations and pharmacokinetic parameters were analyzed and compared between the HI patient groups and healthy matched control groups. The geometric mean ratio (GMR; 90% confidence interval [CI]) for maximum concentration (C

    Topics: Humans; Hypoglycemic Agents; Liver Diseases; Pyrimidines; Thiazolidinediones

2022